Inotiv Surges 23.3% Today - Is There Still Upside?

Inotiv stock is trading -73.5% below its average target price of $26 after marking a 23.3% during today's None session. Analysts are giving the small-cap Diagnostics & Research company an average rating of buy and target prices ranging from $4 to $64 per share.

The stock has an above average percentage of its shares sold short at 14.4%, and a short ratio of 1.48. 25.21% of the corporation's outstanding shares are owned by its managers and directors, indicating a strong degree of alignment between their interests and those of other shareholders. Finally, we also note that only a small number of institutional investors are invested in the stock, with 47.8% of Inotiv's shares being owned by this investor type.

Institutions Invested in Inotiv

Holder Shares Date Reported Percentage Value
Wasatch Advisors Inc 1,399,365 2022-09-29 5% $9,641,624
Blackrock Inc. 1,033,666 2022-09-29 4% $7,121,958
Vanguard Group, Inc. (The) 907,455 2022-09-29 4% $6,252,364
P2 Capital Partners, LLC 715,705 2022-09-29 3% $4,931,207
Janus Henderson Group PLC 567,535 2022-09-29 2% $3,910,316
Point72 Asset Management, L.P. 518,937 2022-09-29 2% $3,575,475
Thrivent Financial For Lutherans 513,286 2022-09-29 2% $3,536,540
Ophir Asset Management Pty Ltd 435,190 2022-09-29 2% $2,998,459
Venator Capital Management Ltd. 410,000 2022-09-29 2% $2,824,899
Renaissance Technologies, LLC 377,565 2022-09-29 1% $2,601,422

Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Inotiv.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.